Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQ001 in Newly Diagnosed Acute Graft Versus Host Disease
NCT03763318Phase 2Completed
- Sponsor
- Biocon
- Start
- Jul 2019
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of itolizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Biocon. Started Jul 2019; status: completed.
02
Drugs
itolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03763318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03763318.